A personalized live human bone graft, reshaping the treatment of bone deficiencies
BonoFill™ is grown from a patient's cells outside the body in a controlled system. It is highly regenerative and can be readily produced for any patient, broadening the scope of bone grafting, enabling a swift return to regular functions, and minimizing the need for revision surgeries
Versatile tissue-engineered graft set to replace autologous bone transfer
With its broad applicability, BonoFill™ addresses a potential market of millions of bone grafting procedures. For healthcare providers, it adds more treatment options for complex cases and can potentially reduce surgery time by up to 70%. For payers, BonoFill™ presents a cost-effective solution, potentially reducing hospitalization and surgery costs by over 50%.
Significant milestones in clinical trials
BonoFill™ has demonstrated remarkable safety and efficacy in two Phase II clinical trials. These trials focused on treating maxillofacial bone deficiencies and critical-sized bone defects in the limbs. Dozens of patients who had previously suffered from years of disabilities and failed treatment options have already recovered thanks to BonoFill™.
Broadly applicable tissue-engineered bone graft
Applicable in variable sizes and bones and designed for bone reconstruction due to various bone diseases or damages: addressing a market of millions of bone grafting procedures.
Clinical Trials
“BonoFill™ is tested in two Phase II clinical trials for treating maxillofacial bone deficiencies and critical-sized bone defects in the limbs, showing remarkable safety and efficacy. Dozens of patients treated with BonoFill™ already recovered after years of disabilities and failing other treatment options.
Pre transplant, the patient’s average residual bone height was 6.6 mm
3 months following BonoFillTM transplantation, average bone height was 14.8 mm
6 months following BonoFillTM transplantation, bone height 15.8 mm, demonstrating new bone growth of 9.2 mm
A Remarkable Recovery: From Injury to Iron Man Competition
Danny Yaakobson, an extreme sports enthusiast, suffered a serious leg injury in a car accident. He became the world's first patient to receive Bonus Biogroup's lab-grown bone implant, BonoFill™, made from his own fat cells. This innovative treatment replaced a missing section of his shinbone. Just 13 months post-transplantation, Danny took part in the ISRAMAN triathlon, cycling for 91 km and marking a remarkable recovery.
info@bonus-bio.com
+972 (0)73 206 7104
Matam Advanced Technology
